Revenue and net profit declined 12.16% and 26.44% year-over-year, respectively, with negative operating cash flow due to higher outflows. Several new drug clinical trial approvals were obtained, while VAT policy changes increased tax rates on biological products.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.